Literature DB >> 27296106

Clinicopathologic Features of Advanced Squamous NSCLC.

Mark A Socinski1, Coleman Obasaju2, David Gandara3, Fred R Hirsch4, Philip Bonomi5, Paul Bunn4, Edward S Kim6, Corey J Langer7, Ronald B Natale8, Silvia Novello9, Luis Paz-Ares10, Maurice Pérol11, Martin Reck12, Suresh S Ramalingam13, Craig H Reynolds14, David R Spigel15, Thomas E Stinchcombe16, Heather Wakelee17, Carlos Mayo2, Nick Thatcher18.   

Abstract

Lung cancer remains the leading cause of cancer-related death worldwide. NSCLC accounts for more than 85% of all lung cancers, and the prognosis for advanced-stage disease is typically poor. In recent years, the importance of histologic subtypes of NSCLC has been recognized, and the distinction between squamous and other NSCLC histologic subtypes is now critical to patient management. Squamous cell lung cancer (sqCLC) represents approximately 25% to 30% of NSCLC. The prognosis for patients with advanced NSCLC is poorer for those with sqCLC than for those with adenocarcinoma. This is partly due to a number of clinical characteristics that distinguish sqCLC from other NSCLC histologic subtypes, such as smoking history, comorbid diseases, age, and molecular profile. Together, these factors make sqCLC an especially challenging disease to manage. Herein, we review some of the key clinicopathologic features of sqCLC. Understanding these features to optimally address many of the unique therapeutic challenges of this disease is likely to be central to ultimately improving outcomes for patients with squamous NSCLC.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Etiology; Histologic Subtype; NSCLC; Squamous cell lung cancer

Mesh:

Substances:

Year:  2016        PMID: 27296106     DOI: 10.1016/j.jtho.2016.05.024

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  34 in total

1.  miR-193b availability is antagonized by LncRNA-SNHG7 for FAIM2-induced tumour progression in non-small cell lung cancer.

Authors:  Kelin She; Hui Yan; Jun Huang; Huaping Zhou; Jianxing He
Journal:  Cell Prolif       Date:  2017-11-12       Impact factor: 6.831

2.  Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells.

Authors:  Qi Lai; Haiyong Wang; Angui Li; Yinhui Xu; Liang Tang; Qiang Chen; Chunfang Zhang; Yang Gao; Jianfei Song; Zhenzong Du
Journal:  Oncogene       Date:  2018-02-09       Impact factor: 9.867

3.  Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.

Authors:  Suresh S Ramalingam; Silvia Novello; Salih Zeki Guclu; Dmitry Bentsion; Zanete Zvirbule; Maria Szilasi; Reyes Bernabe; Konstantinos Syrigos; Lauren Averett Byers; Philip Clingan; Jair Bar; Everett E Vokes; Ramaswamy Govindan; Martin Dunbar; Peter Ansell; Lei He; Xin Huang; Vasudha Sehgal; Jaimee Glasgow; Bruce A Bach; Julien Mazieres
Journal:  J Clin Oncol       Date:  2021-08-26       Impact factor: 44.544

4.  Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study.

Authors:  Xinqing Lin; Suyang Li; Haiyi Deng; Xiaohong Xie; Chao Chen; Longqiu Cai; Yilin Yang; Guihuan Qiu; Zhanhong Xie; Yinyin Qin; Ming Liu; Chengzhi Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-10       Impact factor: 4.553

5.  Accounting for EGFR Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data.

Authors:  Sabine Schmid; Mei Jiang; Wei Xu; Geoffrey Liu; M Catherine Brown; Aline Fares; Miguel Garcia; Joelle Soriano; Mei Dong; Sera Thomas; Takashi Kohno; Leticia Ferro Leal; Nancy Diao; Juntao Xie; Zhichao Wang; David Zaridze; Ivana Holcatova; Jolanta Lissowska; Beata Świątkowska; Dana Mates; Milan Savic; Angela S Wenzlaff; Curtis C Harris; Neil E Caporaso; Hongxia Ma; Guillermo Fernandez-Tardon; Matthew J Barnett; Gary Goodman; Michael P A Davies; Mónica Pérez-Ríos; Fiona Taylor; Eric J Duell; Ben Schoettker; Hermann Brenner; Angeline Andrew; Angela Cox; Alberto Ruano-Ravina; John K Field; Loic Le Marchand; Ying Wang; Chu Chen; Adonina Tardon; Sanjay Shete; Matthew B Schabath; Hongbing Shen; Maria Teresa Landi; Brid M Ryan; Ann G Schwartz; Lihong Qi; Lori C Sakoda; Paul Brennan; Ping Yang; Jie Zhang; David C Christiani; Rui Manuel Reis; Kouya Shiraishi; Rayjean J Hung
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-03-01       Impact factor: 4.090

6.  Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma.

Authors:  Kai Wang; Xiao Qu; Shaorui Liu; Xudong Yang; Fenglong Bie; Yu Wang; Cuicui Huang; Jiajun Du
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-04       Impact factor: 4.553

7.  Predictive relevance of miR-34a, miR-224 and miR-342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy.

Authors:  Vlastimil Kulda; Martin Svaton; Petr Mukensnabl; Kristyna Hrda; Pavel Dvorak; Zbynek Houdek; Katerina Houfkova; Radana Vrzakova; Vaclav Babuska; Milos Pesek; Martin Pesta
Journal:  Oncol Lett       Date:  2017-11-02       Impact factor: 2.967

8.  Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  M A Siciliano; G Caridà; D Ciliberto; M d'Apolito; C Pelaia; D Caracciolo; C Riillo; P Correale; A Galvano; A Russo; V Barbieri; P Tassone; P Tagliaferri
Journal:  ESMO Open       Date:  2022-04-12

Review 9.  [Progress on the Study of Targeting FGFR in Squamous Non-small Cell Lung Cancer].

Authors:  Ming Dong; Tong Li; Jun Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-02-20

10.  Identifying the histologic subtypes of non-small cell lung cancer with computed tomography imaging: a comparative study of capsule net, convolutional neural network, and radiomics.

Authors:  Han Liu; Zhicheng Jiao; Wenjuan Han; Bin Jing
Journal:  Quant Imaging Med Surg       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.